Metastasis-directed therapy for oligometastatic urological tumours: still no second-hand news

For patients presenting with limited metastatic disease burden, known as the oligometastatic state of disease, a more aggressive treatment approach targeting the new or progressive metastatic lesions might improve patient outcome, with no or only limited toxicity to be expected from the treatment. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Berghen, Charlien, Joniau, Steven, Vulsteke, Christof, Albersen, Maarten, Devos, Gaëtan, Rans, Kato, Haustermans, Karin, De Meerleer, Gert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289610/
https://www.ncbi.nlm.nih.gov/pubmed/32565889
http://dx.doi.org/10.3332/ecancer.2020.1036
Descripción
Sumario:For patients presenting with limited metastatic disease burden, known as the oligometastatic state of disease, a more aggressive treatment approach targeting the new or progressive metastatic lesions might improve patient outcome, with no or only limited toxicity to be expected from the treatment. This review provides an overview of the existing evidence and on-going trials on oligometastatic disease and metastasis-directed therapy in the field of renal, bladder and prostate cancer.

Ejemplares similares